The Latanoprost punctal plug drug delivery system (L-PPDS) has performed well in its Phase II CORE trial, according to study data released by the manufacturer, QLT Plug Delivery Inc.
The Latanoprost punctal plug drug delivery system (L-PPDS) has performed well in its Phase II CORE trial, according to study data released by the system's manufacturer, QLT Plug Delivery Inc.
Thirty-eight patients implanted with the L-PPDS, a non-invasive sustained-release drug-eluting device, completed 12 weeks of follow-up in the randomized, double-masked, multicentre study. The patients had a mean age of 65 years (range: 40–87 years) and a mean baseline intraocular pressure (IOP) of 24.4±2.1 mmHg. Patients received a latanoprost dose of 3.5, 14 or 21 µg.
All dose groups achieved a statistically significant reduction in IOP. From baseline to week 12, the overall IOP reduction was 20%. For those receiving a high-dose of latanoprost, a mean IOP reduction of 4.9 mmHg was achieved; for a medium dose, the reduction was 4.8 mmHg, and for a low dose, the reduction was 5.4 mmHg. The L-PPDS was well tolerated; adverse events were mild and transient, and the most common instances were increased tear production and ocular discomfort.
In the next stage of the Phase II trial, QLT will investigate the use of higher doses of latanoprost (minimum 35 µg) with the L-PPDS.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.